Embecta Corp.
General ticker "EMBC" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $688.4M (TTM average)
Embecta Corp. does not follow the US Stock Market performance with the rate: -14.9%.
Estimated limits based on current volatility of 1.3%: low 3.29$, high 3.50$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-05-28, amount 0.01$ (Y1.20%)
- Total employees count: 2100 (-4.5%) as of 2024
- US accounted for 54.1% of revenue in the fiscal year ended 2024-09-30
- Top business risk factors: Supply chain disruptions, Cybersecurity threats, Pandemic risks, Dependence on key products, Geopolitical risks
- Current price 65.5% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [9.64$, 17.37$]
- 2026-09-30 to 2027-09-30 estimated range: [9.50$, 17.25$]
Financial Metrics affecting the EMBC estimates:
- Positive: with PPE of 4.8 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 22.83 > 12.90
- Positive: Operating profit margin, % of 22.41 > 18.39
- Negative: Investing cash flow per share per price, % of -1.11 <= -0.60
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
- Negative: Interest expense per share per price, % of 12.78 > 3.31
- Negative: Inventory ratio change, % of 0.94 > 0.78
- Negative: Shareholder equity ratio, % of -59.64 <= 19.24
Short-term EMBC quotes
Long-term EMBC plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $1,120.80MM | $1,123.10MM | $1,080.40MM |
| Operating Expenses | $899.30MM | $956.30MM | $838.30MM |
| Operating Income | $221.50MM | $166.80MM | $242.10MM |
| Non-Operating Income | $-115.80MM | $-122.60MM | $-105.80MM |
| Interest Expense | $107.00MM | $112.30MM | $107.30MM |
| R&D Expense | $85.20MM | $78.80MM | $37.30MM |
| Income(Loss) | $105.70MM | $44.20MM | $136.30MM |
| Taxes | $35.30MM | $-34.10MM | $40.90MM |
| Net Income(Loss)* | $70.40MM | $78.30MM | $95.40MM |
| Stockholders Equity | $-821.70MM | $-738.30MM | $-650.60MM |
| Inventory | $152.10MM | $171.50MM | $178.60MM |
| Assets | $1,214.40MM | $1,285.30MM | $1,090.90MM |
| Operating Cash Flow | $67.70MM | $35.70MM | $191.70MM |
| Capital expenditure | $26.50MM | $15.80MM | $9.30MM |
| Investing Cash Flow | $-26.50MM | $-15.80MM | $-9.30MM |
| Financing Cash Flow | $-48.70MM | $-73.40MM | $-226.70MM |
| Earnings Per Share** | $1.23 | $1.34 | $1.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.